Beta Drugs vs Dishman Carbogen vs Fredun Pharmaceuticals: Which Stock Should You Track
- October 16, 2026
- Posted by: Lakshit Sharma
- Category: Market
Beta Drugs PE 45.47, mkt cap Rs 2,104 crore. Dishman Carbogen Amcis PE 142.48, mkt cap Rs 2,301 crore. Fredun Pharmaceuticals PE 57.90, mkt cap Rs 2,537 crore.
Quick Answer
Beta Drugs vs Dishman Carbogen Amcis vs Fredun Pharmaceuticals is a side-by-side comparison of three companies from the pharma and healthcare space. On this comparison, Beta Drugs carries a market capitalisation of about Rs 2,104 crore, against Rs 2,301 crore for Dishman Carbogen Amcis and Rs 2,537 crore for Fredun Pharmaceuticals, with return on equity of 16.95%, 1.46% and 11.73% respectively. Each company’s numbers are presented here without a declared preference, since the right stock depends on an investor’s own criteria.
Beta Drugs vs Dishman Carbogen Amcis vs Fredun Pharmaceuticals starts with the core numbers most investors compare within the pharma and healthcare segment: market capitalisation, valuation multiples, profitability, dividend yield and the latest quarterly results. Figures below are sourced as of October 2026 and will shift with daily price moves.
All three names sit in the pharma and healthcare bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses. The sections below cover the company profiles, a valuation table, the latest quarter and a five-quarter trend for revenue and net profit.
Click Here – Get Free Investment Predictions
Beta Drugs, Dishman Carbogen Amcis and Fredun Pharmaceuticals: Company Overview
Beta Drugs is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 2,104 crore, a return on equity of 16.95% and a book value of Rs 221.65 per share. Its quarterly revenue moved from Rs 103.20 crore in June 2025 to Rs 127.13 crore in June 2026, a change of +23.2%.
Dishman Carbogen Amcis is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 2,301 crore, a return on equity of 1.46% and a book value of Rs 425.87 per share. Its quarterly revenue moved from Rs 732.80 crore in June 2025 to Rs 695.80 crore in June 2026, a change of -5.0%.
Fredun Pharmaceuticals is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 2,537 crore, a return on equity of 11.73% and a book value of Rs 162.78 per share. Its quarterly revenue moved from Rs 119.85 crore in June 2025 to Rs 228.25 crore in June 2026, a change of +90.4%.
Beta Drugs vs Dishman Carbogen Amcis vs Fredun Pharmaceuticals: Valuation and Profitability Snapshot
| Metric | Beta Drugs | Dishman Carbogen Amcis | Fredun Pharmaceuticals |
|---|---|---|---|
| Market Cap (approx.) | Rs 2,104 crore | Rs 2,301 crore | Rs 2,537 crore |
| PE Ratio (TTM) | 45.47 | 142.48 | 57.90 |
| PB Ratio | 8.56 | 0.34 | 9.43 |
| Return on Equity (ROE) | 16.95% | 1.46% | 11.73% |
| EPS (TTM, Rs) | 41.74 | 1.03 | 26.50 |
| Dividend Yield | 0.00% | 0.00% | 0.02% |
| Debt to Equity | 0.60 | 0.46 | 0.80 |
| Book Value per Share (Rs) | 221.65 | 425.87 | 162.78 |
Check the Univest Screener for Live Data
On valuation, Beta Drugs trades at a PE of 45.47 and a PB of 8.56, Dishman Carbogen Amcis at a PE of 142.48 and a PB of 0.34, while Fredun Pharmaceuticals trades at a PE of 57.90 and a PB of 9.43. On return on equity, the three post 16.95%, 1.46% and 11.73% respectively, and on dividend yield they stand at 0.00%, 0.00% and 0.02%. Fredun Pharmaceuticals has the highest market capitalisation of the three at Rs 2,537 crore, while Beta Drugs has the lowest at Rs 2,104 crore. Dishman Carbogen Amcis has the highest PE ratio of the three at 142.48, while Beta Drugs has the lowest at 45.47. Beta Drugs has the highest return on equity of the three at 16.95%, while Dishman Carbogen Amcis has the lowest at 1.46%. Fredun Pharmaceuticals has the highest debt to equity ratio of the three at 0.80, while Dishman Carbogen Amcis has the lowest at 0.46. Debt to equity is 0.60, 0.46 and 0.80 for the three respectively.
Beta Drugs vs Dishman Carbogen Amcis vs Fredun Pharmaceuticals: Latest Quarterly Results
| Company | Latest Quarter Revenue | Latest Quarter Net Profit | YoY Change (Revenue) | QoQ Change (Revenue) | YoY Change (Net Profit) |
|---|---|---|---|---|---|
| Beta Drugs | Rs 127.13 crore | Rs 16.49 crore | +23.2% | +31.3% | +40.9% |
| Dishman Carbogen Amcis | Rs 695.80 crore | -Rs 57.88 crore | -5.0% | -19.8% | -347.2% |
| Fredun Pharmaceuticals | Rs 228.25 crore | Rs 13.13 crore | +90.4% | +7.1% | +93.9% |
Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter. A percentage change in net profit is shown as NA where the comparison quarter was a loss or the latest quarter is a loss, since the percentage is not meaningful in that case.
Beta Drugs vs Dishman Carbogen Amcis vs Fredun Pharmaceuticals: Five-Quarter Revenue and Net Profit Trend
The five-quarter view below shows how revenue and net profit moved from June 2025 to June 2026 for each company in Beta Drugs vs Dishman Carbogen Amcis vs Fredun Pharmaceuticals, which helps separate a one-quarter move from a steadier pattern.
Quarterly revenue (Rs crore)
| Quarter | Beta Drugs | Dishman Carbogen Amcis | Fredun Pharmaceuticals |
|---|---|---|---|
| June 2025 | Rs 103.20 crore | Rs 732.80 crore | Rs 119.85 crore |
| September 2025 | Rs 106.38 crore | Rs 660.76 crore | Rs 145.30 crore |
| December 2025 | Rs 89.58 crore | Rs 726.46 crore | Rs 160.93 crore |
| March 2026 | Rs 96.85 crore | Rs 867.82 crore | Rs 213.05 crore |
| June 2026 | Rs 127.13 crore | Rs 695.80 crore | Rs 228.25 crore |
Quarterly net profit (Rs crore)
| Quarter | Beta Drugs | Dishman Carbogen Amcis | Fredun Pharmaceuticals |
|---|---|---|---|
| June 2025 | Rs 11.70 crore | Rs 23.41 crore | Rs 6.77 crore |
| September 2025 | Rs 12.22 crore | Rs 65.27 crore | Rs 9.43 crore |
| December 2025 | Rs 8.52 crore | -Rs 12.97 crore | Rs 10.48 crore |
| March 2026 | Rs 9.05 crore | Rs 21.74 crore | Rs 10.78 crore |
| June 2026 | Rs 16.49 crore | -Rs 57.88 crore | Rs 13.13 crore |
Beta Drugs reported revenue of Rs 103.20 crore in June 2025 and Rs 127.13 crore in June 2026, a change of +23.2% across the period. Its highest quarterly revenue in this window was Rs 127.13 crore in June 2026. Net profit stood at Rs 16.49 crore in June 2026, which is a net profit margin of 12.97%.
Dishman Carbogen Amcis reported revenue of Rs 732.80 crore in June 2025 and Rs 695.80 crore in June 2026, a change of -5.0% across the period. Its highest quarterly revenue in this window was Rs 867.82 crore in March 2026. Net profit stood at -Rs 57.88 crore in June 2026, which is a net profit margin of -8.32% (a net loss for the quarter). Dishman Carbogen Amcis reported a net loss in December 2025 and June 2026.
Fredun Pharmaceuticals reported revenue of Rs 119.85 crore in June 2025 and Rs 228.25 crore in June 2026, a change of +90.4% across the period. Its highest quarterly revenue in this window was Rs 228.25 crore in June 2026. Net profit stood at Rs 13.13 crore in June 2026, which is a net profit margin of 5.75%.
Download the Univest iOS App or Univest Android App to track Beta Drugs, Dishman Carbogen Amcis and Fredun Pharmaceuticals live prices.
What Should Investors Look at Beyond These Numbers?
Beyond the metrics above, investors comparing these three pharma and healthcare names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and factors specific to the segment such as regulatory approvals, export orders, patient volumes and capacity utilisation. A single-quarter snapshot can shift quickly, and smaller companies in particular can show wide swings from one quarter to the next.
It also helps to read the latest quarterly filings and investor presentations of Beta Drugs, Dishman Carbogen Amcis and Fredun Pharmaceuticals directly, since the figures here come from standardised data and do not capture company-specific context such as one-time items, order timing or promoter actions.
Conclusion
Beta Drugs vs Dishman Carbogen Amcis vs Fredun Pharmaceuticals highlights how differently three companies in the same pharma and healthcare segment can look across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information as of October 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Beta Drugs vs Dishman Carbogen Amcis vs Fredun Pharmaceuticals
What is the market cap difference between Beta Drugs, Dishman Carbogen Amcis and Fredun Pharmaceuticals?
Ans. As of October 2026, Beta Drugs has a market cap of approximately Rs 2,104 crore, Dishman Carbogen Amcis is at approximately Rs 2,301 crore, and Fredun Pharmaceuticals is at approximately Rs 2,537 crore. Fredun Pharmaceuticals is the largest of the three, and its market capitalisation is about 1.2 times that of Beta Drugs, the smallest. Market capitalisation reflects the size of a company in the market rather than the quality of its business, so a larger value does not by itself signal a higher quality company. These figures move with the share price every trading day, which is why the table above should be read as a snapshot rather than a fixed ranking in the Beta Drugs vs Dishman Carbogen Amcis vs Fredun Pharmaceuticals comparison.
What are the PE and PB ratios of Beta Drugs, Dishman Carbogen Amcis and Fredun Pharmaceuticals?
Ans. As of October 2026, the PE ratios stand at 45.47, 142.48 and 57.90 respectively, and the price to book ratios stand at 8.56, 0.34 and 9.43 respectively. All three companies have a positive trailing PE, so the multiples can be compared directly. The PE ratio shows how much investors pay for each rupee of trailing earnings, while the PB ratio compares the market value with the net assets on the balance sheet. Both multiples should be read against the segment norms for pharma and healthcare and against each company’s own growth and earnings stability, because a high multiple can reflect expected growth or simply a small earnings base.
Which of the three has the highest ROE?
Ans. Beta Drugs, Dishman Carbogen Amcis and Fredun Pharmaceuticals post ROE of 16.95%, 1.46% and 11.73% respectively as of October 2026. Beta Drugs has the highest return on equity of the three at 16.95%, while Dishman Carbogen Amcis has the lowest at 1.46%. Return on equity measures how much profit a company generates on the capital contributed by its shareholders, so it is a useful gauge of how efficiently equity is being used. A negative ROE points to losses over the period, and a very high ROE can sometimes result from a small equity base rather than operating performance. It is therefore worth reading ROE together with debt levels and the five-quarter profit trend before drawing any conclusion from the Beta Drugs vs Dishman Carbogen Amcis vs Fredun Pharmaceuticals figures.
Which of these three stocks pays the highest dividend yield?
Ans. Beta Drugs, Dishman Carbogen Amcis and Fredun Pharmaceuticals carry dividend yields of 0.00%, 0.00% and 0.02% respectively as of October 2026. Dividend yield is the annual dividend per share expressed as a percentage of the current share price, so it changes whenever the price changes. A low or zero yield is common among companies that retain profits to fund expansion, repay debt or absorb losses, and it does not by itself say anything about business quality. Investors who care about income should also check how consistently each company has paid dividends and what share of profit it distributes.
What is the debt to equity ratio for Beta Drugs, Dishman Carbogen Amcis and Fredun Pharmaceuticals?
Ans. Beta Drugs carries a debt to equity of 0.60, Dishman Carbogen Amcis of 0.46, and Fredun Pharmaceuticals of 0.80. Fredun Pharmaceuticals has the highest debt to equity ratio of the three at 0.80, while Dishman Carbogen Amcis has the lowest at 0.46. The debt to equity ratio compares total borrowings with shareholders’ funds, and a higher figure means the company relies more on borrowed money to run its business. What counts as a comfortable level differs by segment, since some businesses in pharma and healthcare need heavy capital and carry more debt than others. Investors usually read this ratio alongside interest costs and cash generation to judge how well each company can service its borrowings in the Beta Drugs vs Dishman Carbogen Amcis vs Fredun Pharmaceuticals comparison.
What were the latest quarterly revenue and net profit of Beta Drugs, Dishman Carbogen Amcis and Fredun Pharmaceuticals?
Ans. For Q1 FY27 (quarter ended June 2026), Beta Drugs reported revenue of Rs 127.13 crore and net profit of Rs 16.49 crore, Dishman Carbogen Amcis reported revenue of Rs 695.80 crore and net profit of -Rs 57.88 crore, and Fredun Pharmaceuticals reported revenue of Rs 228.25 crore and net profit of Rs 13.13 crore. Compared with the quarter ended June 2025, revenue changed by +23.2% for Beta Drugs, -5.0% for Dishman Carbogen Amcis and +90.4% for Fredun Pharmaceuticals. A single quarter can be affected by seasonality, one-time items and the timing of orders, so the five-quarter tables above give a clearer sense of direction than any one result. A net loss in a quarter does not always mean a troubled business, but it does call for a closer look at costs, debt and the reasons behind the swing in the Beta Drugs vs Dishman Carbogen Amcis vs Fredun Pharmaceuticals results.
Does this comparison recommend one of Beta Drugs, Dishman Carbogen Amcis and Fredun Pharmaceuticals?
Ans. This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor’s own criteria and research. Instead of a verdict, the tables above lay out the figures so that readers can weigh them against their own goals, time horizon and tolerance for risk. For companies in pharma and healthcare, it also helps to look at factors such as regulatory approvals, export orders, patient volumes and capacity utilisation. Reading the latest filings and investor presentations of Beta Drugs, Dishman Carbogen Amcis and Fredun Pharmaceuticals directly, and speaking to a SEBI registered adviser where needed, is a sensible step before acting on any numbers shown in Beta Drugs vs Dishman Carbogen Amcis vs Fredun Pharmaceuticals.